Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of experimental models that reflect the complexity of allergen-IgE interactions. We designed a heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal response and number of immunodominant epitopes observed in natural allergens, thereby providing a physiologically relevant experimental model to study mast cell degranulation. The HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitopeIgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously target the antigen-and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent mast cell degranulation, thus establishing the therapeutic potential of the HBI design.
among the identified epitopes on a given allergen, only one to five are immunodominant, meaning they are involved in the degranulation response observed in the majority of patients with that particular allergy 7, [9] [10] [11] . For example, the peanut allergen Ara h 3, the wheat allergen Tri a 14 and the melon allergen Cuc m 2 were each found to have four distinct epitopes triggering the allergic reaction 6, 12, 13 . Additionally, the melon allergen was found to have two high-binding and two low-binding IgE epitopes (Fig. 1a) 4, 14 .
Owing to the complexity of natural allergens, it has been a challenge to develop experimental models that mimic natural allergic responses. As a result, most allergy studies are performed using dinitrophenyl (DNP) with DNP-specific IgE (IgE DNP ) as the haptenantibody pair [15] [16] [17] [18] [19] . The DNP-IgE DNP system uses monoclonal IgE DNP to bind the IgE receptor, FcεRI, on mast cells. After the mast cells are primed with IgE DNP , cross-linking is induced with DNP-conjugated synthetic allergens typically synthesized using BSA, human serum albumin or ovalbumin as the scaffold. Despite the prevalence of this model, it has several shortcomings. First, DNP binds IgE DNP with an atypically high affinity, which is not representative of the broad range of affinities IgEs have for natural allergy epitopes 10, 13, 20 . Second, the hapten conjugation methods used are nonspecific, resulting in heterogeneous synthetic allergens containing 2 to 25 haptens, which is far more than the number of allergyinducing epitopes found in natural allergens [16] [17] [18] . Furthermore, the heterogeneity of these synthetic allergens complicates interpretation of results as the precise number and orientation of the haptens are unknown, and some haptens may be unavailable to bind surface-bound IgE owing to steric constraints 21, 22 . Finally, multiple presentations of the same hapten on a synthetic allergen do not accurately represent the multiple distinct epitopes on a natural allergen 3, 4 . Although previous studies using the DNP-IgE DNP model have provided important insight into mast cell degranulation, they fall short in modeling the complexity of natural allergen-IgE interactions.
In this study, we developed a well-defined, multicomponent experimental system that enabled an integrative approach to study mast cell degranulation (Fig. 1b,c) . Specifically, in our design, we incorporated (i) epitope heterogeneity, (ii) IgE antibody variability, (iii) range of epitope-IgE affinities and (iv) relevant epitope valency observed in natural allergens to better reflect the complexity of allergen-IgE interactions. This was accomplished through the design of a tetravalent scaffold that allowed four haptens to bind simultaneously to four different IgE antibodies. The flexibility of the design allowed for the simultaneous presentation of four identical haptens, homotetravalent allergens (HmTAs), or two sets of two haptens, HtTAs. In our design, we also controlled the affinities of the IgEhapten interactions by using multiple IgE-hapten pairs and by chemically modifying the haptens to reflect the range of the epitope-IgE affinities present in physiological systems. The tetravalent allergen design provided a more realistic representation of natural allergens and allowed us to investigate the role of weak-affinity epitopes when presented alone or with high-affinity epitopes on a single allergen. Our results demonstrated that low-affinity epitopes have a major role in eliciting an allergic response when presented in combination with high-affinity epitopes.
Next, we evaluated the therapeutic potential of selective inhibition of weak-affinity epitopeIgE interactions by taking an engineering approach where we designed selective and targeted inhibitors (HBIs) of weak-affinity interactions by using the conserved nucleotidebinding site found on the Fab domain of IgE antibodies (Fig. 1d) . Through a combination of molecular modeling and experimental approaches, we have extensively characterized this underused site and demonstrated that this binding site is conserved across all immunoglobulins 17, 23 . In addition, our analysis demonstrated that the conformation of the four residues that make up this binding site, two tyrosine residues on the light chain and one tyrosine and one tryptophan on the heavy chain, are also highly conserved 17, 24, 25 .
Previously, we described in detail the design, synthesis and characterization of HBIs that selectively inhibited allergen binding to IgE antibody, thereby inhibiting mast cell degranulation in a variant of the commonly used DNP-IgE DNP model 17 . HBIs were composed of a hapten molecule conjugated to a nucleotide-binding site ligand, which enabled simultaneous targeting of the antigen-binding site as well the nucleotide-binding site located on the Fab domain of all antibodies (Fig. 1d) . Simultaneous bivalent binding to both of these sites provided the HBIs with enhanced avidity and selectivity for the target IgE and enabled competitive inhibition of allergen binding. In this study, we demonstrated that an HBI designed to selectively inhibit only the weak-affinity epitope-IgE interactions of a HtTA consisting of high-and low-affinity haptens was sufficient to prevent degranulation in both in vitro and in vivo allergy models (Fig. 1e) . Taken together, the HtTA design provided an experimental tool to elucidate formerly unrevealed aspects of mast cell degranulation, and the HBI design provided us with a new antibody-targeting approach with therapeutic potential to selectively inhibit allergic responses.
Results

Design and characterization of tetravalent allergens
Previous methods of synthesizing allergens use nonspecific chemical methods to conjugate haptens to protein scaffolds, resulting in poorly defined allergens that complicate interpretation of results [15] [16] [17] [18] 21, 22 . To address this problem, we synthesized well-defined and well-characterized tetravalent allergens with the criteria that each of the four haptens bound a different IgE. Through a combination of experimental approaches and molecular modeling, it has been demonstrated that the average distance between the two Fab domains of IgE is 11-13 nm and that, owing to the differences between the extended and in-solution length of ethylene glycol, a PEG 3350 linker (extended length of 29 nm) is required to span the two antigen-binding sites on a single IgE [26] [27] [28] . Previously, we identified that ethylene glycol with an extended length of ∼6 nm is optimal for haptens to bind multiple antibodies without bridging the two antigen-binding sites on a single antibody [29] [30] [31] [32] [33] . Consequently, in our tetravalent allergen design, the four hapten moieties were conjugated to the core of the molecule with 8 units of ethylene glycol, which provided an extended length of 3.2 nm, yielding a maximum separation of 6.4 nm between haptens (Fig. 2a,b) . The resulting separation distance between haptens was substantially shorter than the length required for bivalent binding to a single IgE, ensuring that the tetravalent allergen cross-linked the neighboring IgE molecules on mast cells rather than the two Fab arms of a single IgE 28 . Lysine residues were incorporated into the scaffold to provide a means of conjugating each moiety to the ethylene glycol linker as well as to provide a charge to increase the solubility of the synthetic allergens. The flexibility and solubility of the tetravalent scaffold ensured that each hapten was available to bind an IgE antibody, yet the length of the ethylene glycol linker made it sterically unfavorable for a single IgE to bind bivalently to a single tetravalent allergen.
The next step was the identification of haptens with a broad range of affinities for IgE antibodies to reflect the range of affinities found in natural allergy systems. To identify the high-affinity and low-affinity haptens, we determined the monovalent binding affinities of several hapten-IgE pairs using a previously described fluorescence quenching method 17 . Out of the screened candidates, dansyl-IgE dansyl was identified as a high-affinity pair with a monovalent K d dansyl = 54 ± 4 nM (Fig. 3a) . To identify a hapten-IgE pair that could be used to represent the weak-affinity interactions, we modified the commonly used DNP-IgE DNP pair. Although DNP binds IgE DNP with high affinity, we established that nitrofuran (NF) binds IgE DNP with a monovalent K d NF of 41 ± 4 μM (Fig. 3a) . The dansyl-IgE dansyl and NFIgE DNP pairs provided a 760-fold difference in affinity, allowing us to model both the high-and low-affinity epitopes found in natural allergy systems. Notably, inclusion of two different IgE-hapten pairs in our design provided a closer approximation to physiological conditions, where multiple clones of IgEs are involved in mast cell degranulation (Fig. 1b,c) . The HtTA design provided that a degranulation response will only occur if both haptenspecific IgEs are present on the mast cell surface; if only one of the respective IgEs is present, the HtTA will essentially behave as a bivalent ligand, which is insufficient for triggering degranulation 34, 35 . As a first step in demonstrating that both hapten-IgE pairs are necessary for degranulation, we assessed any cross-reactivity between the two haptens; NF did not cross-react with IgE dansyl , and, similarly, dansyl did not cross-react with IgE DNP (Supplementary Results, Supplementary Fig. 1 ).
Next, we synthesized a series of tetravalent synthetic allergens using Fmoc chemistry on a solid support (Fig. 2b) After synthesizing the tetravalent allergens, it was necessary to characterize the molecules to ensure that each hapten was available for simultaneous binding to a separate IgE antibody. This was accomplished by analyzing the complexes formed by a stoichiometric mixture of IgE antibodies to tetravalent allergens (2:1) using dynamic light scattering. The results of a representative experiment performed by mixing HtTA [dansyl 2 NF 2 ] with 2 molar equivalents of IgE (50:50 mixture of IgE DNP and IgE dansyl ) are shown in Figure 3b . Although IgE antibodies had an average hydrodynamic diameter of 10 nm (Fig. 3b) , addition of HtTA [dansyl 2 NF 2 ] to the antibody mixture rapidly resulted in the formation of complexes with a hydrodynamic diameter of 20 nm (Fig. 3b) . Markedly, the signal at 10 nm completely disappeared, indicating that all of the monomeric IgEs were sequestered by the tetravalent allergen. Thermodynamic equilibrium was reached in less than 1 min, and complexes were stable over several hours. Similarly, HmTA [dansyl 4 ] formed complexes with a hydrodynamic diameter of 20 nm with IgE dansyl and, as expected, did not form complexes with IgE DNP (Supplementary Fig. 2 ). The allergen HmTA [NF 4 ] did not form complexes with IgE DNP owing to the low affinity of the NF-IgE DNP interaction ( Supplementary Fig. 2 ). On the basis of these results and the design of the tetravalent scaffold, we concluded that the structure formed was a bicyclic tetramer consisting of four IgEs and two tetravalent allergens (IgE 4 HtTA 2 or IgE 4 HmTA 2 ). The only other possible structure with a hydrodynamic diameter of 20 nm with complete sequestration of IgE is two IgEs binding a single tetravalent allergen (IgE 2 HtTA or IgE 2 HmTA); however, this was eliminated as a possibility on the basis of the design of the tetravalent allergens. Efficient cross-linking of two Fabs on a single IgE requires a hapten separation distance of 11-13 nm, which is substantially longer than the maximum separation distance between haptens in our design 28, 33, 36 . Additionally, the binding of HtTA [dansyl 2 NF 2 ] to IgE dansyl , IgE DNP and an equimolar solution of both IgEs was evaluated using the previously described fluorescence quenching technique 17 . There was a 3.3-fold increase in the affinity of HtTA [dansyl 2 NF 2 ] for IgE DNP in the presence of IgE dansyl compared to IgE DNP alone, thus providing further evidence for the formation of a bicyclic tetramer consisting of four IgEs and two tetravalent allergens ( Supplementary Fig. 3 ). The complexes were not stable for the ∼10 min required for size-exclusion chromatography analysis owing to the weak-affinity haptens. Combined, these results indicated that each hapten on the tetravalent allergen was simultaneously bound to a different IgE, demonstrating that binding of four IgE molecules to the tetravalent allergen was not sterically hindered.
Tetravalent allergens induce degranulation in vitro
Hapten-conjugated BSA is a poor model of natural allergens. However, BSA conjugates have been shown to be potent stimulators of allergic responses [15] [16] [17] . Therefore, we first used hapten-conjugated BSA to optimize our system and assess any cross-reactivity between the antibody-hapten pairs by using the well-established rat basophilic leukemia (RBL) mast cell degranulation model. RBL cells were primed with IgE DNP , IgE dansyl or an equimolar solution of both antibodies. The relative amounts of each IgE on the surface of the mast cells reflected the relative IgE ratios in solution, as determined using a fluorescein-DNP ligand ( Supplementary Fig. 4 ). Our results with BSA allergens dansyl 14 -BSA and NF 17 -BSA (14 and 17 average haptens per BSA respectively) demonstrated that both allergens triggered degranulation when the RBL cells were primed with the hapten-specific IgE or the equimolar solution of both antibodies (Fig. 4a) . The lack of a response by cells primed with IgE DNP using dansyl 14 -BSA as the allergen or cells primed with IgE dansyl using NF 17 -BSA as the allergen demonstrated the specificity of each hapten for the corresponding IgE. These results were consistent with the monovalent affinity assays and further demonstrated that there was no cross-reactivity between the hapten-IgE pairs. This result indicates that (i) both antibodies were able to bind the FcεRI receptors on the cell surface, (ii) the presence of either antibody did not inhibit the other from binding to its hapten and (iii) maximum degranulation does not require complete cross-linking of mast cell-bound IgE. These control experiments validated that RBL cells primed with both IgE DNP and IgE dansyl antibodies provide a suitable experimental system to test the tetravalent synthetic allergens. 4 ] proved to be the most potent allergen, stimulating a bell-shaped dose response from 5 nM to 5 μM with a maximum response at 500 nM (Fig. 4b) . Conversely, HmTA [NF 4 ] did not initiate a degranulation response. Markedly, HtTA [dansyl 2 NF 2 ], which is composed of both dansyl and NF haptens, each with a valency of 2, stimulated a bell-shaped degranulation response from 50 nM to 5 μM, similar to HmTA [dansyl 4 ], with a maximum response occurring at 500 nM. These results were in agreement with our previous work performed with homotetravalent allergens, where we determined that a hapten must have a K d <235 nM to stimulate a response 29 . These results suggested a mechanism of activation where a single hapten binds a single IgE on the surface of a mast cell, and then the allergenIgE complex diffuses laterally across the surface of the mast cell until a second IgE is encountered, and the hapten binds the second IgE, thus cross-linking the receptors. Accordingly, a HmTA with low-affinity haptens will not stay bound to an IgE long enough for complexes to form 29, 33 . Control experiments were performed with HmBA [dansyl 2 ], which did not stimulate a response under any condition. These results were consistent with previous literature reports that bivalent allergens are incapable of stimulating degranulation 34, 35 . Combined, these results indicate that the response observed with HtTA [dansyl 2 NF 2 ] was not due to the dansyl moieties alone (Fig. 4b) (Supplementary Fig. 5 ). Given that the individual components of HtTA (HmTA [NF 4 ] and HmBA [dansyl 2 ]) failed to elicit a degranulation response, these results illustrate the importance of low-affinity epitopes in mast cell degranulation, particularly when presented simultaneously with high-affinity epitopes on the same allergen.
HBI inhibits mast cell degranulation in vitro
Previously, we described HBIs that selectively inhibited allergen binding to IgE antibody, thereby inhibiting mast cell degranulation 17 . HBI (5) was composed of the NF hapten (K d of 41 ± 4 μM for IgE DNP ) conjugated to a nucleotide-binding site ligand, indole-3-butyric acid (IBA; K d of 4.5 ± 0.6 μM for IgE), with an ethylene glycol linker (Fig. 5a ). This design enabled simultaneous targeting of the antigen-binding site as well as of the adjacent nucleotide-binding site located in the Fab of antibodies (Fig. 1d) . Simultaneous bivalent binding to both sites provided HBI with greater than 120-fold enhancement in avidity for IgE DNP compared to monovalent NF 17 . In this study, we investigated the potential of HBI to inhibit mast cell degranulation stimulated by HtTA [dansyl 2 NF 2 ] by selectively and exclusively inhibiting the weak-affinity epitope interactions, specifically the NF-IgE DNP interactions. We predicted that HBI would partially inhibit the binding of HtTA [dansyl 2 NF 2 ] to mast cell-bound IgE by blocking the NF-IgE DNP interaction and that this partial inhibition of allergen binding would effectively lower the valency of the allergen, decreasing its potential to stimulate a response. To test our hypothesis, RBL cells were primed with an equimolar solution of IgE DNP and IgE dansyl and then were exposed to HtTA [dansyl 2 NF 2 ] with increasing concentrations of the HBI (Fig. 5b) . HBI inhibited the degranulation response with a half-maximum effective concentration of 2 μM. The individual components of HBI, ethylene glycol-conjugated NF as a monovalent inhibitor (MI, 6; Fig. 5a ) or IBA did not inhibit degranulation (Fig. 5c,d ). These results demonstrated that both moieties, IBA and NF, were required for the enhanced avidity of HBI for IgE DNP that enabled the competitive inhibition of HtTA [dansyl 2 (Fig. 5e) . Combined, these studies demonstrated that partial inhibition of HtTA [dansyl 2 NF 2 ]-IgE binding by HBIs, which exclusively inhibit only the weak affinity NF-IgE DNP interactions, was sufficient to prevent mast cell degranulation.
HtTA induced degranulation in PCA mouse allergy model
The next step in validating the HtTA experimental system was to demonstrate the ability of HtTA to induce an allergic response in vivo. We selected the passive cutaneous anaphylaxis (PCA) mouse allergy model, a well-established model for studying anaphylaxis in vivo 19, 37 . The HtTA design requires the presence of two IgE antibodies each specific for a different hapten to stimulate degranulation. Consequently, a mixture of 50 ng of IgE DNP and IgE dansyl (right ear) or PBS (left ear) was injected intradermally into C57BL/6 mice. Twenty-four hours later, 1.5 nmol of HtTA [dansyl 2 NF 2 ] was injected intravenously, causing swelling in the ear that received the IgE injection. Then, by comparing the tissue thickness of the ear that received the IgE injection to the ear that received the PBS injection using both micrometer measurements and histology, the severity of the allergic reaction was quantified. The 1.5-nmol dose of HtTA [dansyl 2 NF 2 ] corresponded to an initial blood concentration of ∼1,000 nM, slightly above the concentration that elicited the maximum degranulation response in vitro (assuming mouse blood volume of 1.5 mL). HtTA [dansyl 2 NF 2 ] significantly increased tissue swelling 2 h after challenge when compared with the naive group (P<0.05, Fig. 6 ). Mice treated with DNP-BSA were used as a control and showed a similar increase in ear thickness (Supplementary Fig. 7) . These results validated the utility of the HtTA design as an experimental model system that enables both in vitro and in vivo evaluation of mast cell activation.
HBI inhibits degranulation in PCA mouse allergy model
To evaluate the therapeutic potential of HBI, we next evaluated its inhibitory potential in the PCA mouse allergy model. C57BL/6 mice were injected intradermally with an equimolar mixture of IgE dansyl and IgE DNP (right ear) and PBS (left ear). Twenty-four hours later, mice were challenged intravenously with 1.5 nmol HtTA [dansyl 2 NF 2 ] alone or in combination with HBI as indicated in Figure 6 . The amounts of HBI, 0.5 nmol, 5 nmol and 10 nmol per mouse, were chosen on the basis of the in vitro inhibition data and correspond to initial blood concentrations of ∼0.3-7 μM (1.5-ml blood volume), approximating the range where inhibition was observed in vitro. HBI significantly inhibited ear swelling when compared to nontreated mice in a dose-dependent manner, reaching near-complete inhibition at 10 nmol (P<0.05, Fig. 6 ). This result indicated that HBI blocks the effects of HtTA [dansyl 2 NF 2 ] on tissue inflammation and edema induced by mast cell degranulation. Additionally, these results provided further evidence that inhibition of all of the IgE epitopes on an allergen is not required to effectively inhibit the degranulation response. In fact, inhibition of only a few low-binding epitopes may be sufficient to prevent mast cell degranulation, thus highlighting the therapeutic potential of the HBI design.
Discussion
Previous studies have addressed the role of high-affinity epitopes in mast cell degranulation by using simplified allergen models; however, the importance of low-affinity epitopes have not been sufficiently or properly evaluated. In this study, we established a well-defined synthetic tetravalent allergen system that models the epitope heterogeneity and polyclonal response of natural allergy systems through the multivalent presentation of high-and lowaffinity hapten molecules on the same scaffold. The bivalent presentation of each hapten on the HtTA required the presence of two distinct IgE antibodies to elicit a mast cell degranulation response. As such, the HtTA system better reflected the complexity of IgEepitope interactions observed in natural allergy systems and allowed for the elucidation of the role weak-affinity epitopes have in mast cell degranulation. The tetravalency of the synthetic allergens provided a realistic approximation of the number of immunodominant epitopes present in several common allergens, and having precise control over the valency and structure of the scaffold enabled us to study the effect of affinity on mast cell degranulation without other confounding factors.
Using the HtTA allergen system, we demonstrated that low-affinity epitopes have an important role in mast cell degranulation when presented in combination with high-affinity epitopes on a multivalent allergen. The importance of low-affinity epitopes was demonstrated with the synthetic allergen HtTA [dansyl 2 NF 2 ], which was a potent stimulator of mast cell degranulation, whereas a tetravalent version of NF, HmTA [NF 4 ], and a bivalent version of dansyl, HmBA [dansyl 2 ], did not elicit a response. These results challenge the previous theory that due to the extremely low IgE serum concentration, IgE must have a moderate to high affinity for the specific allergen to stimulate mast cell degranulation 38 . Combined, these experiments illustrate the importance of valency, affinity and cooperativity in allergen-IgE binding interactions in mast cell degranulation, thus highlighting the importance of weak-affinity epitopes in the induction of an allergic response.
To evaluate the therapeutic potential of selective inhibition of weak-affinity epitopes for the inhibition of an allergic response, we used a molecular engineering approach to design the HBI. The HBI was engineered to selectively inhibit only the weak-affinity hapten-IgE interactions by simultaneously targeting the antigen-and nucleotide-binding sites present on the Fab arm of antibodies. The simultaneous bivalent binding provided the HBI with 120-fold enhancement in affinity for IgE DNP compared to monovalent NF, making it a potent inhibitor of mast cell degranulation. Markedly, HBI was a potent inhibitor of HtTA-induced mast cell degranulation in both the in vitro RBL mast cell model and the in vivo PCA mouse model of allergy. Using the HBI design in conjunction with the HtTA allergy model, we demonstrated that inhibition of every epitope-IgE interaction on an allergen was not required for complete inhibition of mast cell degranulation. Rather, partial inhibition of allergen binding to the mast cell-bound IgEs to reduce the allergen valency was sufficient to inhibit the overall mast cell degranulation response. Combined, the results presented here demonstrate the utility of the conserved nucleotide-binding site for the inhibition of allergic reactions and established the HBI design as an effective inhibitor of mast cell degranulation. A major challenge in the current therapies used to treat allergic responses involves the nonspecific suppression of the immune system that puts patients at risk for infections and generates other side effects. Therefore more selective treatment options are needed. Given that most allergens have one to five immunodominant epitopes and that selective inhibition of only a few epitopes are sufficient to inhibit mast cell degranulation, short peptide sequences that mimic an IgE epitope can be used in the HBI design as potential therapeutics for the selective inhibition of food allergies, environmental allergies and asthmas.
Online Methods
Synthesis of the tetravalent and bivalent synthetic allergens
The synthetic allergens were synthesized using Fmoc solid phase synthesis as previously described 33 . Fmoc-protected residues were activated with HBTU or HATU in DMF with DIEA for 3 min, and coupling was monitored with Kaiser tests. Fmoc protecting groups were removed by three exposures to 20% piperidine in DMF for 3 min. The synthetic allergens were synthesized using multiple lysine derivatives to achieve branching while NFmoc-amido-dPEG 8 -acid was used to provide the EG 8 linkers. The syntheses of the synthetic allergens were identical except for the conjugation of the different haptens. The synthetic strategy was as follows: Boc-Lys(Fmoc)-OH was conjugated to NovaPEG Rink Amide resin. After removal of the Fmoc group, a second Boc-Lys(Fmoc)-OH group was added to the molecule, and Fmoc was removed. Next, Fmoc-Lys(ivDde)-OH was conjugated to the molecule. After removal of the Fmoc group, Fmoc-Lys(Fmoc)-OH was conjugated to the ligand to facilitate branching. Both Fmoc groups were removed simultaneously, providing two primary amines for the conjugation of the ethylene glycol linkers. After removing the Fmoc groups on the ethylene glycol linkers, Boc-Lys(Fmoc)-OH was conjugated to each chain followed by the removal of the Fmoc groups. This provided two primary amines for the conjugation of the first set of haptens, NF, dansyl or acetyl. The next step was the removal of the orthogonal protecting group, ivDde, from the previously conjugated lysine residue using 2% hydrazine in DMF. The same branching process was repeated by sequentially conjugating Fmoc-Lys(Fmoc)-OH, N-Fmoc-amindo-dPEG 8 -acid and Boc-Lys(Fmoc)-OH to the molecule, thus providing two additional primary amines for the conjugation of the second set of haptens, dansyl or NF. Conjugation of the haptens was achieved using: dansyl chloride (5-(dimethylamino)naphthalene-1-sulfonyl chloride) for dansyl, 5-nitro-2-furoic acid for NF and acetic anhydride to create the acetyl group. Following synthesis, all of the molecules were cleaved from the resin by two exposures to 92:4:4 TFA/H 2 O/TIS for 30 min. The TFA solution was removed under vacuum, and the molecule was purified using RP-HPLC with a semipreparative Zorbax C18 column (9.4 mm × 250 mm) with a linear solvent gradient of 2.5% min -1 increments in acetonitrile at a 4.0 mL/min flow rate. The purified molecules were characterized with a Bruker micrOTOF II mass spectrometer. Purity was determined with the described HPLC system using a Zorbax C18 analytical column (4.6 mm × 150 mm). The purity of all of the synthesized ligands was estimated to be >97% (Supplementary Fig. 9 29, 33 .
Synthesis of HBI
The HBI was synthesized using Fmoc solid phase synthesis as previously described in detail 17 . The purity was estimated to be >97% (Supplementary Fig. 9 ) by an analytical injection using the previously described HPLC system and was characterized with a Bruker micrOTOF II mass spectrometer. The calculated exact mass of HBI (C 3 8H 56 N 6 O13) was 804.3905 Da; found 805.3928 Da. Characterization matched literature values 17 .
Synthesis of BSA-conjugated allergens
NF was conjugated to BSA using N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), and dansyl was conjugated to BSA using dansyl chloride as previously described 17 . BSA conjugates were purified using 0.5 mL 10-kDa molecular weight cut-off spin concentrators (Millipore), and purity was determined using RP-HPLC and found to be >95% ( Supplementary Fig. 8 )
Fluorescence quenching assay for determination of IgE-hapten binding affinities
The monovalent binding constants of NF and dansyl for IgE DNP and IgE dansyl were determined using the previously described fluorescence quenching assay 17 . Briefly, NF and dansyl quench the fluorescence from the IgE tryptophan residues, occurring at 335 nm, only when the two molecules are in proximity to each other (<10 nm). The monovalent haptens were titrated into a 96-well plate containing a 200-μL solution of 10 nM IgE in PBS. All of the experiments were repeated in at least triplicate.
IgE-HtTA complex formation
Dynamic light scattering experiments were performed with a Malvern Zetasizer Nano S. 
RBL degranulation assay
RBL cells and IgE DNP were kindly provided by Dr. B Wilson (University of New Mexico), and IgE dansyl (clone 27-74) was purchased from BD Biosciences. RBL cells were maintained as described previously 16 . For the degranulation assays, 100 μL of cells were plated at 0.5 × 10 6 cells/mL in a 96-well plate and were incubated for 24 h followed by a 2-h incubation with the IgE antibodies as indicated in Figures 4 and 5 at a total IgE concentration of 1 μg/mL. Cells were washed immediately before experiments and were stimulated with the concentration of allergen as indicated in Figures 4 and 5 for 60 min unless otherwise stated. When testing the allergy inhibitors, the inhibitor was added to cells 30 min before the allergen. Degranulation was detected spectroscopically by measuring the activity of the granule-stored enzyme β-hexosaminidase secreted into the supernatant on the substrate p-nitrophenyl-N-actyl-β-O-glucosamine. All of the degranulation assays were repeated in at least triplicate. In all of the experiments, the total IgE concentration was kept constant at 1 μg/mL. Animals C57BL/6 female mice (7-8 weeks) were obtained from Harlan Biosciences (Indianapolis, IN). Mice were maintained in pathogen-free conditions, and studies were approved by the Indiana University Institutional Animal Care and Use Committee.
PCA
PCA was performed as previously described 19 . Briefly, mice were injected intradermally with PBS (left ear) and an equimolar solution of IgE DNP and IgE dansyl (100 ng total IgE) (right ear). After 24 h, mice were injected intravenously with HtTA [dansyl 2 NF 2 ] (1.5 nmol) and treated with the amount of HBI indicated in Figure 6 . The thickness of ears was measured before HtTA [dansyl 2 NF 2 ] and at 1 h and 2 h after challenge. The data were expressed as change in thickness compared with values before HtTA [dansyl 2 NF 2 ] inoculation.
Statistical analysis
A one-way analysis of variance (ANOVA) for multiple comparisons was performed, and P < 0.05 was considered statistically significant as indicated in Figure 6 .
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. 
